By goal
GLP-1 & Amylin Shots — what actually works, by evidence
Of 21 incretin and amylin drugs used for weight loss and the approved diabetes drugs they descend from, 4 are FDA-approved for that use and 15 more have controlled human trials. The other 2 rest on pilot studies.
Fat loss without the incretin and amylin drugs: Fat-Loss Peptides →
FDA Approved 7
- GLP-1 & Amylin Shots · Weekly shotSemaglutideThe weekly shot the FDA approved as Ozempic and Wegovy. Weight loss in its main trial: 14.9%, on average.Evidence · Approved drugFDA approvedChecked Oct 12
- GLP-1 & Amylin Shots · Weekly shotTirzepatideZepbound: the weekly shot that beat semaglutide head-to-head. Main trial: 20.9% weight loss at 72 weeks.Evidence · Approved drugFDA approvedChecked Oct 5
- GLP-1 & Amylin Shots · Daily shotLiraglutideThe daily shot before Ozempic, approved for teenagers from 12. Its main trial: 8% weight loss at 56 weeks.Evidence · Approved drugFDA approvedChecked Oct 11
- GLP-1 & Amylin Shots · PillOrforglipronFoundayo: a daily weight-loss pill with no fasting rules. Phase 3: 11.2% weight loss at 72 weeks.Evidence · Approved drugFDA approvedChecked Oct 12
- GLP-1 & Amylin Shots · Weekly shotDulaglutideTrulicity: a weekly diabetes shot, not a weight-loss drug. The AWARD trials: 2–5 kg lost.Evidence · Controlled trialsFDA approvedfor another useChecked Oct 5
- GLP-1 & Amylin Shots · Daily shotExenatideByetta, the diabetes shot copied from Gila monster venom. Obese, no diabetes: 3.3% of weight beyond placebo.Evidence · Controlled trialsFDA approvedfor another useChecked Oct 5
- GLP-1 & Amylin Shots · Daily shotPramlintideApproved in 2005 for diabetics on insulin: three shots a day, boxed warning. Not a weight-loss drug.Evidence · Controlled trialsFDA approvedfor another useChecked Oct 4
Gray Market 14
- GLP-1 & Amylin Shots · Weekly shotRetatrutideLilly's triple-hormone shot, unapproved; gray-market copies sell anyway. Phase 3: 25.0% loss at 80 weeks.Evidence · Controlled trialsGray marketChecked Oct 12
- GLP-1 & Amylin Shots · Weekly shotCagrilintideThe other half of Novo's CagriSema combo. Alone it's gray-market; paired, 20.4% weight loss at 68 weeks.Evidence · Controlled trialsGray marketChecked Oct 11
- GLP-1 & Amylin Shots · Weekly shotMazdutidePrescribed in China since 2025; not approved in the US. Main trial: 12.6% weight loss at 32 weeks.Evidence · Controlled trialsGray marketChecked Oct 11
- GLP-1 & Amylin Shots · Weekly shotSurvodutideBoehringer's two-in-one weight-loss shot, in Phase 3. Phase 2 beat placebo by up to 12 points of body weight.Evidence · Controlled trialsGray marketChecked Oct 4
- GLP-1 & Amylin Shots · Weekly shotPetrelintidePitched as the weight-loss shot you can stay on. Phase 2: 9.8% at 28 weeks against 1.7% on placebo.Evidence · Controlled trialsGray marketChecked Oct 5
- GLP-1 & Amylin Shots · Weekly shotEloralintideLilly's next weight-loss shot, in trials only. Phase 2: 20% weight loss at 48 weeks in 263 adults.Evidence · Controlled trialsGray marketChecked Oct 11
- GLP-1 & Amylin Shots · Weekly shotAmycretinNovo's next weight-loss shot and pill, trials only. Every published result: Novo-funded trials, 759 people.Evidence · Controlled trialsGray marketChecked Oct 12
- GLP-1 & Amylin Shots · Weekly shotCagriSemaNovo's two-drug shot built to beat Zepbound. 20.4% weight loss in Phase 3; the FDA hasn't ruled yet.Evidence · Controlled trialsGray marketChecked Oct 11
- GLP-1 & Amylin Shots · Weekly shotEcnoglutideChina's weekly weight-loss shot, billed as beating semaglutide. The proof: a conference poster at week 20.Evidence · Controlled trialsGray marketChecked Oct 4
- GLP-1 & Amylin Shots · Monthly shotMariTideAmgen's bid for a once-a-month obesity shot. In print so far: one efficacy trial, 592 people, Amgen-funded.Evidence · Controlled trialsGray marketChecked Oct 12
- GLP-1 & Amylin Shots · Weekly shotPemvidutideAltimmune's two-in-one weight-loss shot, in trials only. Phase 2: 15.6% loss at 48 weeks in 391 adults.Evidence · Controlled trialsGray marketChecked Oct 11
- GLP-1 & Amylin Shots · Weekly shotVK2735Viking's rival to Mounjaro, in trials only. Phase 2: 14.7% weight loss in 13 weeks at the top dose.Evidence · Controlled trialsGray marketChecked Oct 12
- GLP-1 & Amylin Shots · Weekly shotCT-388Roche's weekly weight-loss shot, still in trials. Phase 2 poster, top dose: 18.3% beyond placebo at 48 weeks.Evidence · Human pilotsGray marketChecked Oct 5
- GLP-1 & Amylin Shots · Weekly shotGlumitideLilly's trial-only shot, built from one half of Zepbound. Data: two Phase 1 studies, four weeks of dosing.Evidence · Human pilotsGray marketChecked Oct 11
- Legal today
- 7 FDA approved · 0 Compounded Rx · 14 Gray market
- What people actually run
- None of the seven named stacks
Status alerts